Clonal hematopoiesis of indeterminate potential (CHIP) is when blood tests find abnormal blood stem cells with genetic changes (mutations) that are early blood cancer signs. Clonal hematopoiesis of indeterminate potential (CHIP), is the presence of acquired mutations in blood cells of an individual in the absence of an overt blood cancer. Clonal hematopoiesis of indeterminate potential (CHIP) refers to a condition when only one such mutation has occurred, and a cell with this mutation can expand to form a family of cells that circulate in the blood.
Most individuals with CHIP never develop cancer. This is why the condition is referred to as CHIP—Clonal Hematopoiesis of Indeterminate Potential. The term “indeterminate potential” reflects the uncertainty of what these mutations mean for your health. Clonal hematopoiesis of indeterminate potential, or CHIP, is a common aging-related phenomenon in which hematopoietic stem cells (HSCs) or other early blood cell progenitors contribute to the formation of a genetically distinct subpopulation of blood cells.
chip medical abbreviation, [1][2][3] As the name suggests, this subpopulation in the blood is characterized by a ... For understanding, there are those conditions with preserved blood counts (i.e., CHIP) compared with those with irregular blood counts (i.e., ICUS and CCUS). There are the disorders with no mutations (i.e., ICUS) and those with somatic mutations confirmed by NGS (i.e., CHIP and CCUS). CHIP stands for c lonal h ematopoiesis of i ndeterminate p otential. CHIP is a precursor condition (early version) of more active blood cancers, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
chip medical abbreviation, Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) are two blood disorders that can increase a person’s risk for developing cancer such as acute myeloid leukemia or myelodysplastic syndrome.
